Duality Advisers, LP Incyte Corp Transaction History

Duality Advisers, LP

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$56.55 - $66.59 $4.34 Million - $5.11 Million	76,812 New	76,812 $4.38 Million
Q3 2023 Nov 02, 2023	BUY	$57.77 - $65.93 $1.84 Million - $2.1 Million	31,829 Added 126.3%	57,031 $3.29 Million
Q2 2023 Jul 31, 2023	SELL	$60.95 - $75.51 $1.99 Million - $2.47 Million	-32,713 Reduced 56.48%	25,202 $1.57 Million
Q1 2023 Jun 27, 2023	BUY	$70.23 - $86.01 $4.07 Million - $4.98 Million	57,915 New	57,915 $4.19 Million
Q3 2022 Nov 03, 2022	SELL	$66.18 - $82.86 $1.99 Million - $2.49 Million	-30,106 Reduced 51.56%	28,283 $1.89 Million
Q2 2022 Aug 08, 2022	BUY	$66.18 - $83.18 $3.86 Million - $4.86 Million	58,389 New	58,389 $4.44 Million
Q4 2021 Feb 02, 2022	SELL	$63.34 - $74.11 $344,062 - $402,565	-5,432 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$68.67 - $84.02 $373,015 - $456,396	5,432 New	5,432 $374,000
Q1 2021 May 13, 2021	SELL	$76.02 - $100.5 $682,659 - $902,490	-8,980 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$80.74 - $97.7 $725,045 - $877,346	8,980 New	8,980 $781,000
Q3 2020 Nov 12, 2020	SELL	$85.07 - $109.69 $973,456 - $1.26 Million	-11,443 Closed	0 $0
Q2 2020 Jul 29, 2020	BUY	$74.18 - $108.93 $848,841 - $1.25 Million	11,443 New	11,443 $0
Q2 2019 Aug 12, 2019	SELL	$73.52 - $88.7 $1.17 Million - $1.41 Million	-15,900 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$63.56 - $88.17 $3.85 Million - $5.34 Million	-60,510 Reduced 79.19%	15,900 $1.37 Million
Q4 2018 Feb 13, 2019	BUY	$58.5 - $69.94 $4.47 Million - $5.34 Million	76,410 New	76,410 $4.86 Million

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.